

Special Issue

Advances in the Pathogenesis and Treatment of Heart Failure and Cardiomyopathy

Message from the Guest Editors

Heart failure (HF) is one of the major challenges in cardiovascular disease, characterized by high morbidity and mortality, with a significant impact on public health expenditure. Current guidelines recommend different classes of drugs, invasive procedures, implantable devices, and lifestyle changes to prevent the progression of HF. Despite advances in recent decades, effective therapeutic interventions remain limited. As a result, progressive cardiac dysfunction, reduced functional capacity, and increased mortality remain commonplace. New, evidence-based therapies are therefore essential. These new approaches will pave the way for promising agents to alter the natural history of HF in the future. This Special Issue aims to contribute to the knowledge of the pathophysiology of HF and cardiomyopathy. We invite authors to submit experimental/laboratory studies investigating new therapies that may prevent or slow the progression of HF, including innovative pharmacologic and gene and cell therapies.

Guest Editors

Prof. Dr. Andrey Jorge Serra

Dr. Ednei Luiz Antonio

Dr. Gianna Mões de Albuquerque-Pontes

Dr. Luis Felipe Neves dos Santos

Deadline for manuscript submissions

30 November 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/235470

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).